These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

288 related articles for article (PubMed ID: 25567841)

  • 1. Comparison of the Immunogenicity of Various Booster Doses of Inactivated Polio Vaccine Delivered Intradermally Versus Intramuscularly to HIV-Infected Adults.
    Troy SB; Kouiavskaia D; Siik J; Kochba E; Beydoun H; Mirochnitchenko O; Levin Y; Khardori N; Chumakov K; Maldonado Y
    J Infect Dis; 2015 Jun; 211(12):1969-76. PubMed ID: 25567841
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Equivalent schedules of intradermal fractional dose versus intramuscular full dose of inactivated polio vaccine for prevention of poliomyelitis.
    Jaiswal N; Singh S; Agarwal A; Chauhan A; Thumburu KK; Kaur H; Singh M
    Cochrane Database Syst Rev; 2019 Dec; 12(12):CD011780. PubMed ID: 31858595
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Intradermal fractional booster dose of inactivated poliomyelitis vaccine with a jet injector in healthy adults.
    Soonawala D; Verdijk P; Wijmenga-Monsuur AJ; Boog CJ; Koedam P; Visser LG; Rots NY
    Vaccine; 2013 Aug; 31(36):3688-94. PubMed ID: 23770332
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immunogenicity of full and fractional dose of inactivated poliovirus vaccine for use in routine immunisation and outbreak response: an open-label, randomised controlled trial.
    Snider CJ; Zaman K; Estivariz CF; Yunus M; Weldon WC; Wannemuehler KA; Oberste MS; Pallansch MA; Wassilak SG; Bari TIA; Anand A
    Lancet; 2019 Jun; 393(10191):2624-2634. PubMed ID: 31104832
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Intradermal inactivated poliovirus vaccine: a preclinical dose-finding study.
    Kouiavskaia D; Mirochnitchenko O; Dragunsky E; Kochba E; Levin Y; Troy S; Chumakov K
    J Infect Dis; 2015 May; 211(9):1447-50. PubMed ID: 25391313
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immunogenicity to poliovirus type 2 following two doses of fractional intradermal inactivated poliovirus vaccine: A novel dose sparing immunization schedule.
    Anand A; Molodecky NA; Pallansch MA; Sutter RW
    Vaccine; 2017 May; 35(22):2993-2998. PubMed ID: 28434691
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Randomized controlled study of fractional doses of inactivated poliovirus vaccine administered intradermally with a needle in the Philippines.
    Cadorna-Carlos J; Vidor E; Bonnet MC
    Int J Infect Dis; 2012 Feb; 16(2):e110-6. PubMed ID: 22153001
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immune responses after fractional doses of inactivated poliovirus vaccine using newly developed intradermal jet injectors: a randomized controlled trial in Cuba.
    Resik S; Tejeda A; Mach O; Fonseca M; Diaz M; Alemany N; Garcia G; Hung LH; Martinez Y; Sutter R
    Vaccine; 2015 Jan; 33(2):307-13. PubMed ID: 25448109
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Intradermal fractional dose inactivated polio vaccine: a review of the literature.
    Nelson KS; Janssen JM; Troy SB; Maldonado Y
    Vaccine; 2012 Jan; 30(2):121-5. PubMed ID: 22100886
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Fractional doses of inactivated poliovirus vaccine in Oman.
    Mohammed AJ; AlAwaidy S; Bawikar S; Kurup PJ; Elamir E; Shaban MM; Sharif SM; van der Avoort HG; Pallansch MA; Malankar P; Burton A; Sreevatsava M; Sutter RW
    N Engl J Med; 2010 Jun; 362(25):2351-9. PubMed ID: 20573923
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Safety and immunogenicity of inactivated poliovirus vaccine schedules for the post-eradication era: a randomised open-label, multicentre, phase 3, non-inferiority trial.
    Bandyopadhyay AS; Gast C; Rivera L; Sáez-Llorens X; Oberste MS; Weldon WC; Modlin J; Clemens R; Costa Clemens SA; Jimeno J; Rüttimann R
    Lancet Infect Dis; 2021 Apr; 21(4):559-568. PubMed ID: 33284114
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Boosting Immune Responses Following Fractional-Dose Inactivated Poliovirus Vaccine: A Randomized, Controlled Trial.
    Resik S; Tejeda A; Diaz M; Okayasu H; Sein C; Molodecky NA; Fonseca M; Alemany N; Garcia G; Hung LH; Martinez Y; Sutter RW
    J Infect Dis; 2017 Jan; 215(2):175-182. PubMed ID: 28073858
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Priming after a fractional dose of inactivated poliovirus vaccine.
    Resik S; Tejeda A; Sutter RW; Diaz M; Sarmiento L; Alemañi N; Garcia G; Fonseca M; Hung LH; Kahn AL; Burton A; Landaverde JM; Aylward RB
    N Engl J Med; 2013 Jan; 368(5):416-24. PubMed ID: 23363495
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Randomized controlled clinical trial of fractional doses of inactivated poliovirus vaccine administered intradermally by needle-free device in Cuba.
    Resik S; Tejeda A; Lago PM; Diaz M; Carmenates A; Sarmiento L; Alemañi N; Galindo B; Burton A; Friede M; Landaverde M; Sutter RW
    J Infect Dis; 2010 May; 201(9):1344-52. PubMed ID: 20350164
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Early priming with inactivated poliovirus vaccine (IPV) and intradermal fractional dose IPV administered by a microneedle device: A randomized controlled trial.
    Anand A; Zaman K; Estívariz CF; Yunus M; Gary HE; Weldon WC; Bari TI; Steven Oberste M; Wassilak SG; Luby SP; Heffelfinger JD; Pallansch MA
    Vaccine; 2015 Nov; 33(48):6816-22. PubMed ID: 26476367
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Needle adapters for intradermal administration of fractional dose of inactivated poliovirus vaccine: Evaluation of immunogenicity and programmatic feasibility in Pakistan.
    Saleem AF; Mach O; Yousafzai MT; Khan A; Weldon WC; Oberste MS; Sutter RW; Zaidi AKM
    Vaccine; 2017 May; 35(24):3209-3214. PubMed ID: 28479178
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Lack of immune interference between inactivated polio vaccine and inactivated rotavirus vaccine co-administered by intramuscular injection in two animal species.
    Wang Y; Zade J; Moon SS; Weldon W; Pisal SS; Glass RI; Dhere RM; Jiang B
    Vaccine; 2019 Jan; 37(5):698-704. PubMed ID: 30626530
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Long-term evaluation of mucosal and systemic immunity and protection conferred by different polio booster vaccines.
    Xiao Y; Daniell H
    Vaccine; 2017 Sep; 35(40):5418-5425. PubMed ID: 28111147
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Safety and immunogenicity of inactivated poliovirus vaccine based on Sabin strains with and without aluminum hydroxide: a phase I trial in healthy adults.
    Verdijk P; Rots NY; van Oijen MG; Oberste MS; Boog CJ; Okayasu H; Sutter RW; Bakker WA
    Vaccine; 2013 Nov; 31(47):5531-6. PubMed ID: 24063976
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Inactivated poliovirus vaccine given alone or in a sequential schedule with bivalent oral poliovirus vaccine in Chilean infants: a randomised, controlled, open-label, phase 4, non-inferiority study.
    O'Ryan M; Bandyopadhyay AS; Villena R; Espinoza M; Novoa J; Weldon WC; Oberste MS; Self S; Borate BR; Asturias EJ; Clemens R; Orenstein W; Jimeno J; Rüttimann R; Costa Clemens SA;
    Lancet Infect Dis; 2015 Nov; 15(11):1273-82. PubMed ID: 26318714
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.